and EXTON, Pa., Aug. 24, 2016 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. ( IDRA ), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today announced the presentation of new pre-clinical data that demonstrates the novel gene-silencing mechanism of action of the third generation antisense (3GA) technology platform. In the presentation, entitled Precise excision of targeted RNA by third generation antisense (3GA) oligonucleotides, Idera scientists presented data that demonstrated that gene-silencing by 3GAs led to excision sites in the targeted mRNA in the region similar to that observed with siRNA. These excision products are different from those observed with earlier generations of antisense. This presentation also provided a demonstration of 3GAs specificity by showing that the incorporation of a mismatch at the region of excision led to the loss of gene-silencing activity. Based on these studies, the company is also conducting studies to further the potential applications of 3GAs in targeting diseases caused by point mutations. Data from these studies is expected to be presented in the second half of 2016. This presentation is currently available on Ideras website at http://www.iderapharma.com/our-science/key-presentations-and-publications . Our in-depth understanding from our pioneering work in antisense technology along with our insights into the interaction of nucleic acids with Toll-like receptors has allowed us to design this very unique technology platform to fully realize the potential of antisense technology, stated Sudhir Agrawal, D. http://www.alabamascholars.org/newgabrielprice/2016/09/13/astute-programs-in-glaucoma-simplified/Phil., President of Research at Idera Pharmaceuticals. We are continuing to conduct preclinical studies with multiple 3GA candidates in house and with our collaborators, with a goal of advancing this technology to clinical development. Previously the company has announced the identification of NLRP3 (NOD-like receptor family, pyrin domain containing protein 3) and DUX4 (Double Homeobox 4) as initial gene targets to advance into IND-enabling activities, which will occur throughout 2016. Potential disease indications related to these targets include, but are not limited to, interstitial cystitis, lupus nephritis, uveitis and facioscapulohumeral muscular dystrophy (FSHD). The Company is currently conducting clinical, regulatory and commercial analysis activities and conducting IND-enabling studies with the plan to enter the clinic in 2017 for the first clinical development program. In addition to these activities, over the first half of 2016, Idera generated 3GA compounds for a series of additional gene targets. These will enable the Company to continue to expand its future pipeline opportunities for both internal development as well as partnerships in areas outside of Ideras focus. Additionally, Idera is party to a collaboration and license agreement with GSK to research, develop and commercialize compounds from its 3GA technology for the treatment of undisclosed, selected renal targets.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/idera-pharmaceuticals-presents-novel-mechanism-110000559.html
The doctor may dilate your eyes or use a special dye to make certain parts easier to see. Some Useful Guidance On Recognising Aspects Of Eye Bags | New Scarlett BurnsOther than avoiding certain infections, including syphilis or HIV, there is no way to prevent uveitis. Smith BR, Spurrier DJ, Martin GT, Rosenbaum GT. If your uveitis was caused by another medical condition, you’ll need to make sure you’re getting the right treatment for it as well. Review. The dye only temporarily stains the eye. Upon entry to the eye, these cells may be returned to an inducible Greg state by the presence of IL-10 and TGF-beta from microglia. A recent NEI-funded study, called the Multicenter Uveitis Treatment Trial MUST, compared the safety and effectiveness of conventional treatment for these forms of uveitis, which suppresses a patient’s entire immune system, with a new local treatment that exclusively suppressed inflammation in the affected eye. She currently practices at One to One Eye Care in San Diego, A. The inflammation can also damage delicate cells on the cornea and retina, causing fluid build-up that blurs and damages the vision, sometimes irreversibly. If the retina is also involved, it is called chorioretinitis. Treatment for uveitis will depend on which areas of the eye are affected and what caused the condition. Some types of anterior uveitis can be chronic or recurrent. She is a fellow of the American Academy of Ophthalmology.
Viruses.an be treated with antiviral medication, bacterial infections can be treated with antibiotics, and fungal infections can be treated with anti fungal medication . So it is important to follow your doctor’s dosage instructions carefully and to keep visiting him or her regularly to monitor the progress of the treatment. Newton, MA: Integrative Medicine Communications; 2000:18;165-166. A Funduscopic Exam: The pupil is widened dilated with eye drops and then a light is shown through with an instrument called an ophthalmoscope to noninvasively inspect the back, inside part of the eye. Herpes Foster eye complications: rates and trends. If the biliary body is also involved, it is called iridocyclitis. The retina is a layer of cells in the back of the eye. These drops dilate your pupils and relieve pain by relaxing the muscles in your eye. If the urea is inflamed in the middle or intermediate region of the eye, it is called pars planitis or intermediate uveitis. In many cases, perhaps as many as a third or half of all uveitis cases, the cause of the inflammation is not known.